AstraZeneca-Oxford Covid-19 vaccine shows an average efficacy of 70%.

Results better than expected for the jab likely to be more accessible to emerging nations due its lower cost and easier storage conditions.

On Monday, the duo announced results from Phase III trials in the UK and Brazil for their coronavirus vaccine showed better than expected efficacy results, with an average efficacy rate of 70% after exploring two dosing regimens. When administered as half a dose followed by a full dose a month later, the vaccine’s efficacy was 90%. When two full doses were given a month apart, this was 62%. Initially the frontrunner, trials for the Oxford jab were halted for suspected safety concerns, which were later shown not to be related to the vaccine. As a result, Pfizer and Moderna raced to the front of the pack, and both released promising results over the past few days.

Pfizer’s and Moderna’s vaccines expected to be sold at profit, and the bulk of their 2021 supplies have already secured by richer nations. However, similarly to J&J's vaccine, Oxford's jab will also be sold at cost in perpetuity for poorer nations. At a cost between USD3 and USD4, the vaccine will be made available at a fraction of the others’ selling price. Furthermore, unlike the others requiring storage conditions as low as -70 degrees Celsius, the Oxford candidate can be stored between 2 and 8 degrees Celsius, making it more accessible for the African continent. The duo plan to submit the data for regulatory approval immediately and will look to produce 3bn doses in 2021.